Icandra

Metformin Hydrochloride and Vildagliptin, the active ingredient in Icandra, is a Biguanide / DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Icandra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icandra combines metformin and vildagliptin to improve glycaemic control in type 2 diabetes.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. Adjunct to diet and exercise in type 2 diabetes: enhances insulin sensitivity and incretin effect. Patients inadequately controlled on metformin alone: provides additional DPP‑4 inhibition for better glucose regulation.

Common Side Effects: - Gastrointestinal upset (nausea, abdominal discomfort) - Diarrhoea - Headache - Dizziness - Upper respiratory tract infection

Serious or Rare Side Effects: - Lactic acidosis (especially with renal impairment) - Severe hypoglycaemia when combined with insulin or sulfonylureas - Acute pancreatitis - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic dysfunction - Renal failure

Before initiating Icandra, consider patient‑specific factors and monitor therapy closely.

Renal function: assess baseline creatinine clearance and monitor periodically. Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. Pregnancy: use only if potential benefit justifies the risk to the fetus. Drug interactions: review all concomitant medications for possible interactions. Monitor blood glucose: adjust dosage based on glycaemic response. Store at ambient temperature: keep in the original container, protect from moisture and light.

Icandra may interact with several medicines; careful review is required.

Major Interactions (Avoid): - Concomitant use with cimetidine: may increase metformin plasma levels. - Combination with sulfonylureas or insulin: heightened risk of hypoglycaemia. - Iodinated contrast agents: can precipitate renal dysfunction with metformin. - Strong CYP3A4 inhibitors: may affect vildagliptin metabolism. - Excessive alcohol intake: raises risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal clearance of metformin. - Beta‑blockers: can mask hypoglycaemia symptoms. - Thyroid hormones: may influence glucose metabolism. - ACE inhibitors or ARBs: monitor renal function when combined. - Statins: watch for signs of myopathy.